Foley & Lardner LLP Partner Jessica Lochmann is quoted in the Law360 article, “New Buyback Rules Put Companies’ Motives Under Spotlight,” discussing new disclosures mandated by the U.S. Securities and Exchange Commission that will see greater scrutiny placed upon company buyback programs.
Companies should prepare to justify their buyback programs in greater detail, and Lochmann said to limit liability for misleading disclosures, corporate executives and boards should carefully examine whether their communications on buyback policies are materially accurate and complete.
“And those reasons and rationales may change over time,” Lochmann added. “I don’t think that language should be boilerplate.”
(Subscription required)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”